S 033188

Drug Profile

S 033188

Alternative Names: RG 6152; S-033188

Latest Information Update: 15 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shionogi
  • Class Antivirals; Small molecules
  • Mechanism of Action Endonuclease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Influenza virus infections
  • Preclinical Influenza A virus H5N1 subtype

Most Recent Events

  • 13 Sep 2017 Shionogi announces intention to submit NDA to US FDA for Influenza virus infections
  • 13 Sep 2017 Efficacy data from the phase III CAPSTONE-1 trial in Influenza virus infections released by Shionogi
  • 24 Jul 2017 Efficacy and adverse events data from a phase III trial in Influenza virus infection released by Shionogi
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top